New therapies for transfusion dependent MDS patients from erythroid Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Alan List speaks to ecancer at ASH 2018 about new therapies for transfusion dependent myelodysplastic syndrome (MDS) patients.nnHe explains that treatments for lower risk MDS patients with anaemia have a short duration of response, therefore there is a need for more effective treatments. One of these is luspatercept, an erythroid maturation agent.nnDr List discusses the results of the Phase III MEDALIST trial, concluding that the use of luspatercept was very durable and that the vast majority
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)